{"id":528,"date":"2026-08-06T12:11:43","date_gmt":"2026-08-06T12:11:43","guid":{"rendered":"https:\/\/www.merckconnect.com\/idvynso\/?page_id=528"},"modified":"2026-08-20T08:41:37","modified_gmt":"2026-08-20T08:41:37","slug":"trial-051-study-design","status":"publish","type":"page","link":"https:\/\/www.merckconnect.com\/idvynso\/trial-051-study-design\/","title":{"rendered":"Trial 051 – Study design"},"content":{"rendered":"\n\n
<\/div>\n\n\n\n\n
<\/div>\"\"<\/picture>

Trial 051 study design & baseline characteristics<\/h1>

<\/p>

<\/div>
<\/div><\/div><\/div><\/div>
<\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n\n

Trial 051 study design<\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n
\n\n
\n

In open-label Trial 051, participants switched from an oral baseline antiretroviral therapy (ART) regimen to IDVYNSO. <\/p><\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n

A total of 551 participants were randomized (2:1) and switched to once-daily IDVYNSO (n=366) or remained on their baseline ART (n=185). Randomization was stratified by baseline ART.\u200b<\/p><\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n

Primary efficacy endpoint:<\/strong> Proportion of participants with HIV-1<\/span>\u2028RNA \u226550 copies\/mL at Week 48.<\/p><\/div><\/div>\n\n\n\n

<\/div>\n<\/div>\n\n\n\n
\n\n
\n
\n

Inclusion criteria<\/strong><\/h3><\/div>\n\n\n\n
<\/div>\n\n\n\n\n
\n